Intraductal carcinoma of the prostate

From Libre Pathology
Jump to navigation Jump to search

Intraductal carcinoma of the prostate, abbreviated IDC-P, is a proliferation of malignant prostate cells within glands that have an intact basal cell layer.

Intraductal carcinoma of the prostate
Diagnosis in short

Intraductal carcinoma of prostate. H&E stain.
LM major criteria : glands 2x normal (peripheral zone) glands, basal cells present, "cytologically malignant cells" (nuclear hyperchromasia, nuclear enlargement, nucleoli), fills the lumen ("expansile") but does not have to be "solid", +/-comedonecrosis; minor criteria : branching of ducts at right angles, rounded/smooth gland outlines, two cell populations (malignant appearing at periphery of gland, benign appearing - centre of gland)
LM DDx invasive prostatic carcinoma, high grade prostatic intraepithelial neoplasia
IHC basal cells are present (CK34betaE12 +ve, p63 +ve)
Site prostate gland
Prevalence uncommon
Blood work PSA typically elevated
Prognosis poor, strongly suggestive invasion if not present

It should not be confused with ductal adenocarcinoma of the prostate gland.

General

  • May represent a precursor to invasive prostate carcinoma.[1]
  • Associated with a poor prognosis.[2]
  • Strong association with aggressive invasive carcinomas on prostatectomy when identified in isolation on biopsy.[3]
  • High interobserver variability among experts ~43% agreement.[4]
    • For comparison: HGPIN ~70% agreement, invasive carcinoma ~73% agreement.
  • Uncommon finding ~ 3% of cases in a series of 1176 prostate biopsies.[5]

Microscopic

Epstein criteria

Epstein's IDCP criteria:[6]

  • "Large" acini or ducts with basal cells and one of the following:
  1. Solid growth pattern or "dense" cribriform pattern.
  2. Micropapillary pattern or "loose" cribriform pattern with one of the following:
    1. Marked atypia 6x normal (area).
    2. Non-focal comedonecrosis.

Zhou criteria

Major criteria

Required major criteria:[7][8]

  1. Glands 2x normal (peripheral zone) glands.
  2. Basal cells present (proven by IHC).
  3. "Cytologically malignant cells" = nuclear hyperchromasia, nuclear enlargement, nucleoli.
  4. Fills the lumen ("expansile") but does not have to be "solid".
    • Solid = no spaces between the cells.

Additional (major) criterion:[7]

Minor criteria

Minor criteria:[7]

  1. Branching of ducts at right angles.
  2. Rounded/smooth gland outlines.
  3. Two cell populations:
    • Malignant population (enlarged nuclei with hyperchromasia and nucleoli) = peripheral location in gland.
    • Benign population (smaller nuclei, no nucleoli) = central location in gland.

DDx

Images

Case 1

  • IDCP - low mag.

  • IDCP - intermed. mag.

  • IDCP - intermed. mag.

  • IDCP - high mag.

  • IDCP - very high mag.

  • IDCP - very high mag.

Case 2

  • IDCP - intermed. mag.

  • IDCP - high mag.

  • IDCP - very high mag.

  • IDCP - very high mag.

IHC

Features - basal cells present:

  • CK34betaE12 +ve.
  • p63 +ve.

See also

References

  1. ↑ Miyai, K.; Divatia, MK.; Shen, SS.; Miles, BJ.; Ayala, AG.; Ro, JY. (2014). "Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.". Int J Clin Exp Pathol 7 (5): 2518-26. PMID 24966964.
  2. ↑ Henry, PC.; Evans, AJ. (Jul 2009). "Intraductal carcinoma of the prostate: a distinct histopathological entity with important prognostic implications.". J Clin Pathol 62 (7): 579-83. doi:10.1136/jcp.2009.065003. PMID 19246509.
  3. ↑ Robinson, BD.; Epstein, JI. (Oct 2010). "Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings.". J Urol 184 (4): 1328-33. doi:10.1016/j.juro.2010.06.017. PMID 20723921.
  4. ↑ Iczkowski, KA.; Egevad, L.; Ma, J.; Harding-Jackson, N.; Algaba, F.; Billis, A.; Camparo, P.; Cheng, L. et al. (Dec 2014). "Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.". Ann Diagn Pathol 18 (6): 333-42. doi:10.1016/j.anndiagpath.2014.08.010. PMID 25263387.
  5. ↑ Watts, K.; Li, J.; Magi-Galluzzi, C.; Zhou, M. (Oct 2013). "Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study.". Histopathology 63 (4): 574-9. doi:10.1111/his.12198. PMID 23931616.
  6. ↑ Guo, CC.; Epstein, JI. (Dec 2006). "Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.". Mod Pathol 19 (12): 1528-35. doi:10.1038/modpathol.3800702. PMID 16980940.
  7. ↑ 7.0 7.1 7.2 Shah, RB.; Zhou, M. (Jul 2012). "Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate.". Adv Anat Pathol 19 (4): 270-8. doi:10.1097/PAP.0b013e31825c6c0e. PMID 22692290.
  8. ↑ Cohen, RJ.; Wheeler, TM.; Bonkhoff, H.; Rubin, MA. (Jul 2007). "A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.". Arch Pathol Lab Med 131 (7): 1103-9. doi:10.1043/1543-2165(2007)131[1103:APOTIH]2.0.CO;2. PMID 17616999.
Retrieved from "https://librepathology.org/w/index.php?title=Intraductal_carcinoma_of_the_prostate&oldid=48796"